Rituximab in treatment of anti-GBM antibody glomerulonephritis: A case report and literature review

RATIONALE: Anti-glomerular basement membrane (GBM) disease is a T cell-mediated disease that has a poor prognosis with conventional therapy. We tested rituximab as a primary therapy to reduce anti-GBM antibody produced by B cells. PATIENT CONCERNS: A 53-year old woman with complaints of a fever, hea...

Descripción completa

Detalles Bibliográficos
Autores principales: Uematsu-Uchida, Mayu, Ohira, Takehiro, Tomita, Shigeki, Satonaka, Hiroshi, Tojo, Akihiro, Ishimitsu, Toshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
5200
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946414/
https://www.ncbi.nlm.nih.gov/pubmed/31689860
http://dx.doi.org/10.1097/MD.0000000000017801

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946414/
https://www.ncbi.nlm.nih.gov/pubmed/31689860
http://dx.doi.org/10.1097/MD.0000000000017801

Ejemplares similares